US 11,859,008 B2
Antibodies for treatment of cancer expressing claudin 6
Ugur Sahin, Mainz (DE); Ozlem Tureci, Mainz (DE); Michael Koslowski, Oberschleißheim (DE); Korden Walter, Wiesbaden (DE); Stefan Woll, Nackenheim (DE); Maria Kreuzberg, Mainz (DE); Bernd Hubner, Munich (DE); Michael Erdeljan, Mainz (DE); and Michael Weichel, Bad Konig (DE)
Assigned to Ganymed Pharmaceuticals GmbH, Mainz (DE); and Johannes Gutenberg-Universität Mainz, Mainz (DE)
Filed by Ganymed Pharmaceuticals GmbH, Mainz (DE); and Johannes Gutenberg-Universitat Mainz, Mainz (DE)
Filed on Dec. 30, 2020, as Appl. No. 17/138,403.
Application 16/028,210 is a division of application No. 15/076,536, filed on Mar. 21, 2016, granted, now 10,233,253, issued on Mar. 19, 2019.
Application 15/076,536 is a division of application No. 14/117,118, granted, now 9,321,842, issued on Apr. 26, 2016, previously published as PCT/EP2012/001721, filed on Apr. 20, 2012.
Application 17/138,403 is a continuation of application No. 16/028,210, filed on Jul. 5, 2018, granted, now 10,919,974.
Claims priority of provisional application 61/486,071, filed on May 13, 2011.
Claims priority of application No. 11004004 (EP), filed on May 13, 2011.
Prior Publication US 2021/0179730 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 39/39591 (2013.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 12 Claims
 
1. A method of producing a transformed cell, the method comprising the steps of:
(a) transforming a human host cell with one or more expression vectors, wherein the one or more expression vectors comprise:
(i) a nucleic acid sequence encoding a first polypeptide comprising the antibody heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 26-33, positions 51-58, and positions 97-106 of SEQ ID NO: 36, respectively; and
(ii) a nucleic acid sequence encoding a second polypeptide comprising the antibody light chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 27-31, positions 49-51, and positions 88-97 of SEQ ID NO: 35, respectively;
(b) culturing the transformed human host cell under conditions in which the transformed human host cell expresses the first and second polypeptides encoded by the one or more expression vectors; and
(c) harvesting the transformed human host cell expressing the first and second polypeptides.